Skip to main content

and
  1. No Access

    Chapter

    Crossing the Blood-Brain Barrier with AAVs: What’s After SMA?

    The 2009 discovery that the AAV9 serotype can deliver genes across the blood-brain barrier (BBB) spurred the rapid development of a recently FDA-approved gene therapy for spinal muscular atrophy (SMA). The suc...

    Yujia Alina Chan, Benjamin E. Deverman in Drug Delivery to the Brain (2022)